{"title":"降压药使用者患帕金森病的风险:来自观察性研究荟萃分析的证据","authors":"Amarnath Mullapudi, Kapil Gudala, Chandra Sekhar Boya, Dipika Bansal","doi":"10.1155/2016/5780809","DOIUrl":null,"url":null,"abstract":"<p><p>Background. Antihypertensive agents have been shown to inhibit oxidative stress and inflammatory response and thus neuroprotection in Parkinson's disease (PD). Epidemiological evidence suggests inconsistency between use of antihypertensives and risk of PD. This study is aimed to examine the association between antihypertensive use and risk of PD. Methods. Literature search in PubMed, EMBASE, and PsycINFO database was undertaken through February 2012 looking for observational studies evaluating the association between antihypertensive drug use and risk of PD. Before meta-analysis, the studies were evaluated for publication bias and heterogeneity. Pooled relative risk (RR) estimates and 95% confidence intervals (CIs) were calculated using random-effects model (DerSimonian and Laird method). Subgroup analyses and sensitivity analysis were also performed. Results. Seven relevant studies including a total of 28,32,991 subjects were included. Pooled RR of overall use of antihypertensive agents was found to be 0.95 (95% CI 0.84-1.05). A significant reduction in the risk of PD was observed among users of calcium channel blockers (RR 0.82, 95% CI 0.71-0.93). Significant heterogeneity (I (2) = 76.2%) but no publication bias was observed. Conclusions. Overall use of antihypertensive agents showed no significant association with the risk of PD. CCBs provided significant protective role. However, studies with large sample size and dose relationships are required to strengthen our hypothesis. </p>","PeriodicalId":16405,"journal":{"name":"Journal of Neurodegenerative Diseases","volume":"2016 ","pages":"5780809"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2016/5780809","citationCount":"17","resultStr":"{\"title\":\"Risk of Parkinson's Disease in the Users of Antihypertensive Agents: An Evidence from the Meta-Analysis of Observational Studies.\",\"authors\":\"Amarnath Mullapudi, Kapil Gudala, Chandra Sekhar Boya, Dipika Bansal\",\"doi\":\"10.1155/2016/5780809\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Background. Antihypertensive agents have been shown to inhibit oxidative stress and inflammatory response and thus neuroprotection in Parkinson's disease (PD). Epidemiological evidence suggests inconsistency between use of antihypertensives and risk of PD. This study is aimed to examine the association between antihypertensive use and risk of PD. Methods. Literature search in PubMed, EMBASE, and PsycINFO database was undertaken through February 2012 looking for observational studies evaluating the association between antihypertensive drug use and risk of PD. Before meta-analysis, the studies were evaluated for publication bias and heterogeneity. Pooled relative risk (RR) estimates and 95% confidence intervals (CIs) were calculated using random-effects model (DerSimonian and Laird method). Subgroup analyses and sensitivity analysis were also performed. Results. Seven relevant studies including a total of 28,32,991 subjects were included. Pooled RR of overall use of antihypertensive agents was found to be 0.95 (95% CI 0.84-1.05). A significant reduction in the risk of PD was observed among users of calcium channel blockers (RR 0.82, 95% CI 0.71-0.93). Significant heterogeneity (I (2) = 76.2%) but no publication bias was observed. Conclusions. Overall use of antihypertensive agents showed no significant association with the risk of PD. CCBs provided significant protective role. However, studies with large sample size and dose relationships are required to strengthen our hypothesis. </p>\",\"PeriodicalId\":16405,\"journal\":{\"name\":\"Journal of Neurodegenerative Diseases\",\"volume\":\"2016 \",\"pages\":\"5780809\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2016/5780809\",\"citationCount\":\"17\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Neurodegenerative Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2016/5780809\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2016/7/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neurodegenerative Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2016/5780809","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/7/19 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 17
摘要
背景。降压药已被证明可以抑制氧化应激和炎症反应,从而保护帕金森病(PD)的神经。流行病学证据表明抗高血压药物的使用与PD的风险不一致。本研究旨在探讨抗高血压药物使用与PD风险之间的关系。方法。2012年2月,在PubMed、EMBASE和PsycINFO数据库中进行文献检索,寻找评估抗高血压药物使用与PD风险之间关系的观察性研究。在荟萃分析之前,对这些研究进行了发表偏倚和异质性评估。采用随机效应模型(DerSimonian和Laird方法)计算合并相对危险度(RR)估计值和95%置信区间(ci)。并进行亚组分析和敏感性分析。结果。纳入7项相关研究,共28,32,991名受试者。总体使用降压药的合并RR为0.95 (95% CI 0.84-1.05)。在钙通道阻滞剂的使用者中观察到PD的风险显著降低(RR 0.82, 95% CI 0.71-0.93)。异质性显著(I(2) = 76.2%),但未观察到发表偏倚。结论。降压药的总体使用与PD的风险无显著相关性。CCBs具有显著的保护作用。然而,需要大样本量和剂量关系的研究来加强我们的假设。
Risk of Parkinson's Disease in the Users of Antihypertensive Agents: An Evidence from the Meta-Analysis of Observational Studies.
Background. Antihypertensive agents have been shown to inhibit oxidative stress and inflammatory response and thus neuroprotection in Parkinson's disease (PD). Epidemiological evidence suggests inconsistency between use of antihypertensives and risk of PD. This study is aimed to examine the association between antihypertensive use and risk of PD. Methods. Literature search in PubMed, EMBASE, and PsycINFO database was undertaken through February 2012 looking for observational studies evaluating the association between antihypertensive drug use and risk of PD. Before meta-analysis, the studies were evaluated for publication bias and heterogeneity. Pooled relative risk (RR) estimates and 95% confidence intervals (CIs) were calculated using random-effects model (DerSimonian and Laird method). Subgroup analyses and sensitivity analysis were also performed. Results. Seven relevant studies including a total of 28,32,991 subjects were included. Pooled RR of overall use of antihypertensive agents was found to be 0.95 (95% CI 0.84-1.05). A significant reduction in the risk of PD was observed among users of calcium channel blockers (RR 0.82, 95% CI 0.71-0.93). Significant heterogeneity (I (2) = 76.2%) but no publication bias was observed. Conclusions. Overall use of antihypertensive agents showed no significant association with the risk of PD. CCBs provided significant protective role. However, studies with large sample size and dose relationships are required to strengthen our hypothesis.